Abcam, ab272703, Anti-Acetyl Coenzyme A carboxylase alpha antibody [EPR23235-47] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal ACACA antibody. Carrier free. Suitable for IP, WB, ICC/IF, Flow Cyt (Intra), IHC-P and reacts with Human, Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR23235-47,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:IHC-P, IP, Flow Cyt (Intra), ICC/IF, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab272703 is the carrier-free version of
ab269272
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Acetyl Coenzyme A Carboxylase Alpha also known as ACC1 is an important enzyme in fatty acid metabolism. It catalyzes the carboxylation of acetyl CoA to form malonyl CoA a critical step in fatty acid synthesis. ACC1 is a large protein with a mass of approximately 265 kDa and is mainly expressed in lipogenic tissues such as liver and adipose tissue. Additional isoforms have been identified with distinct tissue distribution patterns which allow for the regulation of fatty acid metabolism across different tissues.
Biological function summary
Acetyl Coenzyme A Carboxylase Alpha controls the availability of malonyl CoA serving as an important regulator of de novo lipogenesis. It functions as part of a homodimeric complex which is necessary for its optimal enzymatic activity. This regulation contributes to the balance of energy storage and consumption in cells. ACC1 not only facilitates the synthesis of long-chain fatty acids but also coordinates with other cellular processes that depend on lipid availability.
Pathways
ACC1 plays a central role in the fatty acid biosynthesis and energy metabolism pathways. It acts in concert with fatty acid synthase to promote production of fatty acids. ACC1's activity is modulated by several factors including AMP-activated protein kinase (AMPK) which phosphorylates ACC1 leading to its inhibition when energy levels are low. This positioning within the metabolism pathways makes ACC1 a critical point for controlling lipid biosynthesis in response to nutritional and hormonal signals.
Alterations in the activity of Acetyl Coenzyme A Carboxylase Alpha are implicated in conditions such as obesity and type 2 diabetes. Dysregulation of ACC1 leads to aberrant lipid accumulation in tissues contributing to obesity-related insulin resistance. Furthermore the link between ACC1 and fatty acid metabolism associates it with metabolic syndromes. The potential of ACC1 as a pharmacological target has led to research exploring its inhibition as a therapeutic strategy for these metabolic disorders.